All News
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s.
This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too
ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr
Links:
David Liew drdavidliew ( View Tweet)
EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Points to consider in pregnancy &lactation in Pts w #rheumatic #diseases
#biologics don’t increase rate of serious infections in
Mom
Baby
Compared to other matched pregnant and post partum women
reassuring!
#EULAR2024
@RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
What to use in men prior to planned conception of partner in
#rheumatic #diseases
#EULAR2024 @RheumNow @ACRheum @eular_org https://t.co/jMecV8jqUe
Janet Pope Janetbirdope ( View Tweet)
MINIMAL SPINAL RADIOGRAPHIC PROGRESSION in RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS OVER 2 YEARS OF BIMEKIZUMAB TREATMENT: RESULTS FROM A PHASE 3 OPEN-LABEL EXTENSION STUDY - 90% nonprogressers on Bime including how many would never have progressed ? @RheumNow #EULAR2024
Peter Nash drpnash ( View Tweet)
Points to consider in pregnancy in
#rheumatic diseases
3 points
✅TNFi all OK 👍
? Only if you can’t control disease use other #bDMARDs
Baby #vaccinations if exposed to #biologics while present
#rotovirus ok
other live vaccines >6 mos
#EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh
Links:
Janet Pope Janetbirdope ( View Tweet)
POS0231 Safety of JAKi vs TNFi or IL-17 inhibitors in #PsA & #SpA
Results from a large population-based study show reassuring data, with no increased risk of #CVD, #VTE or certain cancers compared to TNFi or IL-17i
@SteZhao @RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s @RheumNow #EULAR2024 https://t.co/SM5CA7KUvd
Peter Nash drpnash ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New reccs for knee/hip #OA w/2 overarching principles
1. Biopsychosocial approach
2.Individualized Rx w/shared decision making (includes education, diet/exercise, healthy weight, appropriate assistive device/footware, modify work factors, pain coping skills)
#EULAR24
@rheumnow https://t.co/0LVLBMGO7L
TheDaoIndex KDAO2011 ( View Tweet)
Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Thanks for these updates recommendations for hip/knee OA -- but, still not much has changed. #eular2034 https://t.co/NMwFWxwocF
Dr. John Cush RheumNow ( View Tweet)
The Role of Psychosocial Determinants in the Management of RA
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
https://t.co/o3vqHJnQHz https://t.co/ibMrNNCmUr
Dr. John Cush RheumNow ( View Tweet)
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria:
OP0195
LBA0005
POS0803
OP0138
https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY
Dr. John Cush RheumNow ( View Tweet)
AI meets Rheumatology: ChatGPT and patient response optimization
Large language models like ChatGPT, trained on vast text data, are revolutionizing healthcare by understanding and generating human-like language.
https://t.co/GzT9UvndTX https://t.co/ziOh8oCbZ9
Dr. John Cush RheumNow ( View Tweet)
A beautiful free concert in Vienna
#EULAR2024 @eular_org @RheumNow https://t.co/8YPWbkmTUr
Janet Pope Janetbirdope ( View Tweet)